NCT04521686 2026-04-22Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT06282575 2026-03-24Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz PharmaceuticalsPhase 3 Recruiting286 enrolled